ArticleNature2022
An LKB1-mitochondria axis controls T
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 88 citations in OpenAlex.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Cancer letters · 2026Review
- Liver Kinase B1 in CD11cAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Why is the tumor microenvironment disordered by NADH/NADRedox biology · 2026Review
- Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases.Cell communication and signaling : CCS · 2026Review
- Liver kinase B1 maintains natural killer cell survival by regulating redox homeostasis.Cell death & disease · 2026Article
- Neutrophil membrane-coated and MMP2-responsive nanoparticles deliver PIM1 inhibitor to alleviate inflammatory arthritis through inhibiting Th17 cell differentiation.Journal of nanobiotechnology · 2026Article
- Receptor-Mitochondria Crosstalk in the Kynurenine Metabolic Pathway: Integrating Metabolomics and Clinical Mass Spectrometry.Antioxidants (Basel, Switzerland) · 2026Review
- Article
- PI3K/Akt/mTOR signaling pathway mediates energy metabolic reprogramming and regulates mitochondrial homeostasis in host cells exposed toMicrobiology spectrum · 2026Article
- ETV1 Drives CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Metabolomics Reveals Potential Biomarkers for Early Detection of irAEs in ICI-Treated Patients.Drug design, development and therapy · 2026Article
- Cristae Architecture as a Metabolic Checkpoint in Effector T Cells - Implications for Cancer Immunity.Journal of cancer immunology · 2026Article
- Mitochondrial fission and fusion in inflammatory diseases: mechanisms and therapeutic implications.Journal of translational medicine · 2025Review
- Article
- Autoimmune disease risk gene ANKRD55 promotes TH17 effector function through metabolic modulation.The Journal of experimental medicine · 2025Article
- Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mitochondrial and lysosomal signaling orchestrates heterogeneous metabolic states of regulatory T cells.Science immunology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 4 institutions in 2 countries.
Francesc BaixauliMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Klara Piletic *Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Daniel J Puleston *Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-8437-0732
Matteo Villa *Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Cameron S FieldMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Lea J FlachsmannMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Andrea QuintanaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Nisha RanaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Joy Edwards-HicksMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Mai MatsushitaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Michal A StanczakMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Katarzyna M GrzesMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Agnieszka M KabatMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Mario FabriMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-9586-2230
George CaputaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Beth KellyMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Mauro CorradoMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-0617-3274
Yaarub MusaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Katarzyna J DudaMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-5256-2641
Gerhard MittlerMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0003-2634-0487
David O'SullivanMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0001-5151-8924
Hiromi SesakiDepartment of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thomas JenuweinMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
Joerg M BuescherMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0002-6547-0076
Edward J PearceMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.
David E SaninMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0188-7267
Erika L PearceMax Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany. epearce6@jhmi.edu.ORCID http://orcid.org/0000-0001-5592-5439
Max Planck Institute of Immunobiology and Epigenetics · DEBloomberg (United States) · USJohns Hopkins University · USUniversity of Cologne · DE
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MStructure, Turnover and Safeguard of MitochondriaR35GM144103 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Hiromi Sesaki · 2022 to 2026
$2.8MPhosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T CellsR01AI156274 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PEARCE, ERIKA L · 2021 to 2025
$2.6MNCI NIH HHS P30 CA006973NIAID NIH HHS R01 AI156274NIGMS NIH HHS R35 GM144103Wellcome Trust
Abstract
CD4
Indexed as
AMP-Activated Protein KinasesMitochondriaTh17 CellsCitric Acid CycleGlutamineGlutaratesGTP PhosphohydrolasesInterleukin-17NADPhosphoglycerate DehydrogenaseSerinealpha-hydroxyglutarateAMP-Activated Protein KinasesGlutamineGlutaratesGTP PhosphohydrolasesInterleukin-17NADPhosphoglycerate DehydrogenaseSerine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.